Suppression of tumour angiogenesis, through platelet factor-4 (PF4), endostatin, and angiostatin, and the chemotherapeutic agent paclitaxel could reverse tumour anergy resulting in strengthened lymphocyte–EC associations by increased expression of endothelial adhesion molecules in tumour blood vessels [58,63]. Here, COL18A1 is linked to neoplasm.